The rational phase of therapeutic angiogenesis

Minerva Cardioangiologica

Volumn 51, Issue 5, 2003, Pages 421-432

  Post, M J ^a,b   Simons, M ^b,c  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b DARTMOUTH MEDICAL SCHOOL   (United States)

^c DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

Author keywords

Growth factors; Myocardial ischemia; Neovascularization, physiologic

Indexed keywords

ANGIOGENIC FACTOR; ANGIOSTATIN; FIBROBLAST GROWTH FACTOR 1; FIBROBLAST GROWTH FACTOR 2; FIBROBLAST GROWTH FACTOR 4; FIBROBLAST GROWTH FACTOR 5; GROWTH FACTOR; HOX PROTEIN; HYPOXIA INDUCIBLE FACTOR 1ALPHA; NITRIC OXIDE SYNTHASE; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR A; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BB; PR 39; PROTEIN DEL 1; PROTEIN KINASE C; SCATTER FACTOR; SCLEROPROTEIN; SOMATOMEDIN B; SOMATOMEDIN C; UNCLASSIFIED DRUG; UNINDEXED DRUG; VASCULOTROPIN; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN C; VASCULOTROPIN D; VASCULOTROPIN E; VASCULOTROPIN RECEPTOR 1; VASCULOTROPIN RECEPTOR 2;

ANGINA PECTORIS; ANGIOGENESIS; ATHEROSCLEROSIS; DIABETIC RETINOPATHY; DISEASE EXACERBATION; DRUG EFFECT; DRUG MECHANISM; GENE THERAPY; HEART MUSCLE BLOOD FLOW; HEART MUSCLE ISCHEMIA; HEART MUSCLE REPERFUSION; HUMAN; NONHUMAN; REVIEW; TUMOR;

GENES, SWITCH; GROWTH SUBSTANCES; HUMANS; MYOCARDIAL ISCHEMIA; NEOVASCULARIZATION, PHYSIOLOGIC;

EID: 0346789112     PISSN: 00264725     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (112)

1. Ware JA, Simons M. Angiogenesis and cardiovascular disease. New York: Oxford University Press; 1999.
2. Xie MH, Holcomb I, Deuel B, Dowd P, Huang A, Vagts A et al. FGF-19, a novel fibroblast growth factor with unique specificity for FGFR4. Cytokine 1999;11:729-35.
3. Yamashita T, Yoshioka M, Itoh N. Identification of a novel fibroblast growth factor, FGF-23, preferentially expressed in the ventrolateral thalamic nucleus of the brain. Biochem Biophys Res Commun 2000;277:494-8.
4. Gospodarowicz D, Cheng J, Lui GM, Baird A, Esch F, Bohlen P. Corpus luteum angiogenic factor is related to fibroblast growth factor. Endocrinology 1985;117:2383-91.
5. Montesano R, Vassalli JD, Baird A, Guillemin R, Orci L. Basic fibroblast growth factor induces angiogenesis in vitro. Proc Natl Acad Sci U S A 1986;83:7297-301.
6. Battler A, Scheinowitz M, Bor A, Hasdai D, Vered Z, Di Segni E et al. Intracoronary injection of basic fibroblast growth factor enhances angiogenesis in infarcted swine myocardium. J Am Coll Cardiol 1993;22:2001-6.
7. Yanagisawa-Miwa A, Uchida Y, Nakamura F, Tomaru T, Kido H, Kamijo T et al. Salvage of infarcted myocardium by angiogenic action of basic fibroblast growth factor. Science 1992;257:1401-3.
8. Roth D, Maruoka Y, Rogers J, White F, Longhurst J, Bloor C. Development of coronary collateral circulation in left circumflex Ameroid-occluded swine myocardium. Am J Physiol 1987;253(5 Pt 2):H1279-88.
9. White F, Carroll S, Magnet A, Bloor C. Coronary collateral development in swine after coronary artery occlusion. Circ Res 1992;71:1490-500.
10. Unger EF, Banai S, Shou M, Jaklitsch M, Hodge E, Correa R et al. A model to assess interventions to improve collateral blood flow: continuous administration of agents into the left coronary artery in dogs. Cardiovasc Res 1993;27:785-91.
11. Lazarous DF, Scheinowitz M, Shou M, Hodge E, Rajanayagam S, Hunsberger S et al. Effects of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart. Circulation 1995;91:145-53.
12. Harada K, Grossman W, Friedman M, Edelman ER, Prasad PV, Keighley CS et al. Basic fibroblast growth factor improves myocardial function in chronically ischemic porcine hearts. J Clin Invest 1994;94:623-30.
13. Lopez JJ, Edelman ER, Stamler A, Hibberd MG, Prasad P, Caputo RP et al. Basic fibroblast growth factor in a porcine model of chronic myocardial ischemia: a comparison of angiographic, echocardiographic and coronary flow parameters. J Pharmacol Exp Ther 1997;282: 385-90.
14. Laham RJ, Rezaee M, Post M, Novicki D, Sellke FW, Pearlman JD et al. Intrapericardial delivery of fibroblast growth factor-2 induces neovascularization in a porcine model of chronic myocardial ischemia. J Pharmacol Exp Ther 2000;292:795-802.
15. Devlin GP, Fort S, Yu E, Cusimano RJ, Wei K, Rakowski H et al. Effect of a single bolus of intracoronary basic fibroblast growth factor on perfusion in an ischemic porcine model. Can J Cardiol 1999;15:676-82.
16. Rajanayagam MA, Shou M, Thirumurti V, Lazarous DF, Quyyumi AA, Goncalves L et al. Intracoronary basic fibroblast growth factor enhances myocardial collateral perfusion in dogs. J Am Coll Cardiol 2000;35:519-26.
17. Sato K, Laham RJ, Pearlman JD, Novicki D, Sellke FW, Simons M et al. Efficacy of intracoronary intravenous FGF-2 in a pig model of chronic myocardial ischemia. Ann Thorac Surg 2000;70:2113-8.
18. Banai S, Jaklitsch MT, Casscells W, Shou M, Shrivastav S, Correa R et al. Effects of acidic fibroblast growth factor on normal and ischemic myocardium. Circ Res 1991;69:76-85.
19. Unger EF, Shou M, Sheffield CD, Hodge E, Jaye M, Epstein SE. Extracardiac to coronary anastomoses support regional left ventricular function in dogs. Am J Physiol 1993;264:H1567-74.
20. Ortega S, Schaeffer MT, Soderman D, DiSalvo J, Linemeyer DL, Gimenez-Gallego G et al. Conversion of cysteine to serine residues alters the activity, stability, and heparin dependence of acidic fibroblast growth factor. J Biol Chem 1991;266:5842-6.
21. Lopez JJ, Edelman ER, Stamler A, Hibberd MG, Prasad P, Thomas KA et al. Angiogenic potential of perivascularly delivered aFGF in a porcine model of chronic myocardial ischemia. Am J Physiol 1998;274:H930-6.
22. Deroanne CF, Hajitou A, Calberg-Bacq CM, Nusgens BV, Lapiere CM. Angiogenesis by fibroblast growth factor 4 is mediated through an autocrine up-regulation of vascular endothelial growth factor expression. Cancer Res 1997;57:5590-7.
23. Giordano FJ, Ping P, McKirnan MD, Nozaki S, DeMaria AN, Dillmann WH et al. Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart. Nat Med 1996;2:534-9.
24. Rissanen TT, Markkanen JE, Arve K, Rutanen J, Kettunen MI, Vajanto I et al. Fibroblast growth factor 4 induces vascular permeability, angiogenesis and arteriogenesis in a rabbit hindlimb ischemia model. Faseb J 2003;17:100-2.
25. FGF-4 gene therapy GENERX - Collateral Therapeutics. BioDrugs 2002;16:75-6.
26. Kasahara H, Tanaka E, Fukuyama N, Sato E, Sakamoto H, Tabata Y et al. Biodegradable gelatin hydrogel potentiates the angiogenic effect of fibroblast growth factor 4 plasmid in rabbit hindlimb ischemia. J Am Coll Cardiol 2003;41:1056-62.
27. Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD et al. Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris. Circulation 2002;105:1291-7.
28. Schlaudraff K, Schumacher B, von Specht BU, Seitelberger R, Schlosser V, Fasol R. Growth of "new" coronary vascular structures by angiogenetic growth factors. Eur J Cardiothorac Surg 1993;7:637-43; discussion 643-4.
29. Lee LY, Patel SR, Hackett NR, Mack CA, Polce DR, El-Sawy T et al. Focal angiogen therapy using intramyocardial delivery of an adenovirus vector coding for vascular endothelial growth factor 121. Ann Thorac Surg 2000;69:14-23; discussion 23-4.
30. Sato K, Wu T, Laham RJ, Johnson RB, Douglas P, Li J et al. Efficacy of intracoronary or intravenous VEGF165 in a pig model of chronic myocardial ischemia. J Am Coll Cardiol 2001;37:616-23.
31. Roethy W, Fiehn E, Suehiro K, Gu A, Yi GH, Shimizu J et al. A growth factor mixture that significantly enhances angiogenesis in vivo. J Pharmacol Exp Ther 2001;299:494-500.
32. Tabata H, Silver M, Isner JM. Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo: critical role of secretion signal in use of naked DNA. Cardiovasc Res 1997;35:470-9. [Erratum in Cardiovasc Res 1998;38:272].
33. Tabata H, Silver M, Isner JM. Arterial gene transfer of acidic fibroblast growth factor for therapeutic angiogenesis in vivo: critical role of secretion signal in use of naked DNA. Cardiovasc Res 1997;35:470-9. [Erratum in Cardiovasc Res 1998;38:272].
34. Rosengart TK, Budenbender KT, Duenas M, Mack CA, Zhang QX, Isom OW. Therapeutic angiogenesis: a comparative study of the angiogenic potential of acidic fibroblast growth factor and heparin. J Vasc Surg 1997;26:302-12.
35. Baffour R, Berman J, Garb JL, Rhee SW, Kaufman J, Friedmann P. Enhanced angiogenesis and growth of collaterals by in vivo administration of recombinant basic fibroblast growth factor in a rabbit model of acute lower limb ischemia: dose-response effect of basic fibroblast growth factor. J Vasc Surg 1992;16:181-91.
36. Baffour R, Garb JL, Kaufman J, Berman J, Rhee SW, Norris MA et al. Angiogenic therapy for the chronically ischemic lower limb in a rabbit model. J Surg Res 2000;93:219-29.
37. Stavri GT, Zachary IC, Baskerville PA, Martin JF, Erusalimsky JD. Basic fibroblast growth factor upregulates the expression of vascular endothelial growth factor in vascular smooth muscle cells. Synergistic interaction with hypoxia. Circulation 1995;92:11-4.
38. Hata Y, Rook SL, Aiello LP. Basic fibroblast growth factor induces expression of VEGF receptor KDR through a protein kinase C and p44/p42 mitogen-activated protein kinase-dependent pathway. Diabetes 1999;48:1145-55.
39. Cuevas P, Reimers D, Carceller F, Martinez-Coso V, Redondo-Horcajo M, Saenz de Tejada I et al. Fibroblast growth factor-1 prevents myocardial apoptosis triggered by ischemia reperfusion injury. Eur J Med Res 1997;2:465-8.
40. Jiang ZS, Padua RR, Ju H, Doble BW, Jin Y, Hao J et al. Acute protection of ischemic heart by FGF-2: involvement of FGF-2 receptors and protein kinase C. Am J Physiol Heart Circ Physiol 2002;282:H1071-80.
41. Huang Z, Chen K, Huang PL, Finklestein SP, Moskowitz MA. bFGF ameliorates focal ischemic injury by blood flow-independent mechanisms in eNOS mutant mice. Am J Physiol 1997;272:H1401-5.
42. Cuevas P, Carceller F, Lozano RM, Crespo A, Zazo M, Gimenez-Gallego G. Protection of rat myocardium by mitogenic and non-mitogenic fibroblast growth factor during post-ischemic reperfusion. Growth Factors 1997;15:29-40.
43. Ferrara N, Alitalo K. Clinical applications of angiogenic growth factors and their inhibitors. Nat Med 1999;5:1359-64.
44. Banai S, Jaklitsch MT, Shou M, Lazarous DF, Scheinowitz M, Biro S et al. Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs. Circulation 1994;89:2183-9.
45. Harada K, Friedman M, Lopez JJ, Wang SY, Li J, Prasad PV et al. Vascular endothelial growth factor administration in chronic myocardial ischemia. Am J Physiol 1996;270:H1791-802.
46. Lopez JJ, Laham RJ, Stamler A, Pearlman JD, Bunting S, Kaplan A et al. VEGF administration in chronic myocardial ischemia in pigs. Cardiovasc Res 1998;40:272-81.
47. Lazarous DF, Shou M, Scheinowitz M, Hodge E, Thirumurti V, Kitsiou AN et al. Comparative effects of basic fibroblast growth factor and vascular endothelial growth factor on coronary collateral development and the arterial response to injury. Circulation 1996;94:1074-82.
48. Takeshita S, Pu LQ, Stein LA, Sniderman AD, Bunting S, Ferrara N et al. Intramuscular administration of vascular endothelial growth factor induces dose-dependent collateral artery augmentation in a rabbit model of chronic limb ischemia. Circulation 1994;90:11228-34.
49. Takeshita S, Rossow ST, Kearney M, Zheng LP, Bauters C, Bunting S et al. Time course of increased cellular proliferation in collateral arteries after administration of vascular endothelial growth factor in a rabbit model of lower limb vascular insufficiency. Am J Pathol 1995;147:1649-60.
50. Takeshita S, Weir L, Chen D, Zheng LP, Riessen R, Bauters C et al. Therapeutic angiogenesis following arterial gene transfer of vascular endothelial growth factor in a rabbit model of hindlimb ischemia. Biochem Biophys Res Commun 1996;227:628-35.
51. Gowdak LH, Poliakova L, Wang X, Kovesdi I, Fishbein KW, Zacheo A et al. Adenovirus-mediated VEGF(121) gene transfer stimulates angiogenesis in normoperfused skeletal muscle and preserves tissue perfusion after induction of ischemia. Circulation 2000;102:565-71.
52. Isner JM, Pieczek A, Schainfeld R, Blair R, Haley L, Asahara T et al. Clinical evidence of angiogenesis after arterial gene transfer of phVEGF165 in patient with ischaemic limb. Lancet 1996;348:370-4.
53. Silvestre JS, Tamarat R, Ebrahimian TG, Le-Roux A, Clergue M, Emmanuel F et al. Vascular endothelial growth factor-B promotes in vivo angiogenesis. Circ Res 2003;93:114-23.
54. Witzenbichler B, Asahara T, Murohara T, Silver M, Spyridopoulos I, Magner M et al. Vascular endothelial growth factor-C (VEGF-C/VEGF-2) promotes angiogenesis in the setting of tissue ischemia. Am J Pathol 1998;153:381-94.
55. Rissanen TF, Markkanen JE, Gruchala M, Heikura T, Puranen A, Kettunen MI et al. VEGF-D is the strongest angiogenic and lymphangiogenic effector among VEGFs delivered into skeletal muscle via adenoviruses. Circ Res 2003;92:1098-106.
56. Luttun A, Tjwa M, Moons L, Wu Y, Angelillo-Scherrer A, Liao F et al. Revascularization of ischemic tissues by PIGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt. Nat Med 2002;8:831-40.
57. LeCouter J, Moritz DR, Li B, Phillips GL, Liang XH, Gerber HP et al. Angiogenesis-independent endothelial protection of liver: role of VEGFR-1. Science 2003;299:890-3.
58. Hattori K, Dias S, Heissig B, Hackett NR, Lyden D, Tateno M et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med 2001;193:1005-14.
59. Asahara T, Takahashi T, Masuda H, Kalka C, Chen D, Iwaguro H et al. VEGF contributes to postnatal neovascularization by mobilizing bone marrow-derived endothelial progenitor cells. EMBO J 1999;18:3964-72.
60. Hattori K, Heissig B, Wu Y, Dias S, Tejada R, Ferris B et al. Placental growth factor reconstitutes hematopoiesis by recruiting VEGFR1(+) stem cells from bonemarrow microenvironment. Nat Med 2002;8:841-9.
61. Nakamura Y, Morishita R, Higaki J, Kida I, Aoki M, Moriguchi A et al. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor. J Hypertens 1996;14:1067-72.
62. Ono K, Matsumori A, Shioi T, Furukawa Y, Sasayama S. Enhanced expression of hepatocyte growth factor/c-Met by myocardial ischemia and reperfusion in a rat model. Circulation 1997;95:2552-8.
63. Morishita R, Nakamura S, Hayashi S, Taniyama Y, Moriguchi A, Nagano T et al. Therapeutic angiogenesis induced by human recombinant hepatocyte growth factor in rabbit hind limb ischemia model as cytokine supplement therapy. Hypertension 1999;33:1379-84.
64. Taniyama Y, Morishita R, Hiraoka K, Aoki M, Nakagami H, Yamasaki K et al. Therapeutic angiogenesis induced by human hepatocyte growth factor gene in rAT diabetic hind limb ischemia model: molecular mechanisms of delayed angiogenesis in diabetes. Circulation 2001;104: 2344-50.
65. Li Y, Takemura G, Kosai K, Yuge K, Nagano S, Esaki M et al. Postinfarction treatment with an adenoviral vector expressing hepatocyte growth factor relieves chronic left ventricular remodeling and dysfunction in mice. Circulation 2003;107:2499-506.
66. Ahmet I, Sawa Y, Yamaguchi T, Matsuda H. Gene transfer of hepatocyte growth factor improves angiogenesis and function of chronic ischemic myocardium in canine heart. Ann Thorac Surg 2003;75:1283-7.
67. Nakamura T, Mizuno S, Matsumoto K, Sawa Y, Matsuda H. Myocardial protection from ischemia/reperfusion injury by endogenous and exogenous HGF. J Clin Invest 2000;106:1511-9.
68. Miyagawa S, Sawa Y, Taketani S, Kawaguchi N, Nakamura T, Matsuura N et al. Myocardial regeneration therapy for heart failure: hepatocyte growth factor enhances the effect of cellular cardiomyoplasty. Circulation 2002;105:2556-61.
69. Bergsten E, Uutela M, Li X, Pietras K, Ostman A, Heldin CH et al. PDGF-D is a specific, protease-activated ligand for the PDGF beta-receptor. Nat Cell Biol 2001;3: 512-6.
70. Heldin CH, Westermark B. Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev 1999;79:1283-316.
71. Battegay EJ, Rupp J, Iruela-Arispe L, Sage EH, Pech M. PDGF-BB modulates endothelial proliferation and angiogenesis in vitro via PDGF beta-receptors. J Cell Biol 1994;125:917-28.
72. Risau W, Drexler H, Mironov V, Smits A, Siegbahn A, Funa K et al. Platelet-derived growth factor is angiogenic in vivo. Growth Factors 1992;7:261-6.
73. Betsholtz C, Karlsson L, Lindahl P. Developmental roles of platelet-derived growth factors. Bioessays 2001;23: 494-507.
74. Post MJ, Pawliuk R, Leboulch P, Arbuckle B, Palac RT, Beaver T et al. Intramyocardial slow release PDGF-BB dose dependently improves perfusion and function in a pig model of cardiac ischemia. Circulation 2002;106 Suppl II:II-37.
75. Edelberg JM, Lee SH, Kaur M, Tang L, Feirt NM, McCabe S et al. Platelet-derived growth factor-AB limits the extent of myocardial infarction in a rat model: feasibility of restoring impaired angiogenic capacity in the aging heart. Circulation 2002;105:608-13.
76. Smiell JM. Clinical safety of becaplermin (rhPDGF-BB) gel. Becaplermin Studies Group. Am J Surg 1998;176: 68S-73S.
77. Hirschi KK, Rohovsky SA, Beck LH, Smith SR, D'Amore PA. Endothelial cells modulate the proliferation of mural cell precursors via platelet-derived growth factor-BB and heterotypic cell contact. Circ Res 1999;84: 298-305.
78. Lindahl P, Johansson BR, Leveen P, Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997;277:242-5.
79. Brown DM, Hong SP, Farrell CL, Pierce GF, Khouri RK. Platelet-derived growth factor BB induces functional vascular anastomoses in vivo. Proc Natl Acad Sci U S A 1995;92:5920-4.
80. Martins RN, Chleboun JO, Sellers P, Sleigh M, Muir J. The role of PDGF-BB on the development of the collateral circulation after acute arterial occlusion. Growth Factors 1994;10:299-306.
81. Brogi E, Wu T, Namiki A, Isner JM. Indirect angiogenic cytokines upregulate VEGF and bFGF gene expression in vascular smooth muscle cells, whereas hypoxia upregulates VEGF expression only. Circulation 1994;90:649-52.
82. Fujio Y, Nguyen T, Wencker D, Kitsis RN, Walsh K. Akt promotes survival of cardiomyocytes in vitro and protects against ischemia-reperfusion injury in mouse heart. Circulation 2000;101:660-7.
83. Su EJ, Cioffi CL, Stefansson S, Mittereder N, Garay M, Hreniuk D et al. Gene therapy vector-mediated expression of insulin-like growth factors protects cardiomyocytes from apoptosis and enhances neovascularization. Am J Physiol Heart Circ Physiol 2003;284:H1429-40.
84. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999;5:1390-5.
85. Ruotolo G, Bavenholm P, Brismar K, Efendic S, Ericsson CG, de Faire U et al. Serum insulin-like growth factor-I level is independently associated with coronary artery disease progression in young male survivors of myocardial infarction: beneficial effects of bezafibrate treatment. J Am Coll Cardiol 2000;35:647-54.
86. Punglia RS, Lu M, Hsu J, Kuroki M, Tolentino MJ, Keough K et al. Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes 1997;46:1619-26.
87. Zhong J, Eliceiri B, Stupack D, Penta K, Sakamoto G, Quertermous T et al. Neovascularization of ischemic tissues by gene delivery of the extracellular matrix protein Del-1. J Clin Invest 2003;112:30-41.
88. Friedlander M, Brooks PC, Shaffer RW, Kincaid CM, Varner JA, Cheresh DA. Definition of two angiogenic pathways by distinct alpha v integrins. Science 1995;270:500-2.
89. Eliceiri BP, Puente XS, Hood JD, Stupack DG, Schlaepfer DD, Huang XZ et al. Src-mediated coupling of focal adhesion kinase to integrin alpha(v)beta5 in vascular endothelial growth factor signaling. J Cell Biol 2002;157:49-60.
90. Hou D, Maclaughlin F, Thiesse M, Panchal VR, Bekkers BC, Wilson EA et al. Widespread regional myocardial transfection by plasmid encoding Del-1 following retrograde coronary venous delivery. Catheter Cardiovasc Interv 2003;58:207-11.
91. Shyu KG, Chang H, Isner JM. Synergistic effect of angiopoietin-1 and vascular endothelial growth factor on neoangiogenesis in hypercholesterolemic rabbit model with acute hindlimb ischemia. Life Sci 2003;73: 563-79.
92. Cao R, Brakenhielm E, Pawliuk R, Wariaro D, Post MJ, Wahlberg E et al. Angiogenic synergism, vascular stability and improvement of hind-limb ischemia by a combination of PDGF-BB and FGF-2. Nat Med 2003;9:604-13.
93. Dor Y, Djonov V, Abramovitch R, Itin A, Fishman GI, Carmeliet P et al. Conditional switching of VEGF provides new insights into adult neovascularization and pro-angiogenic therapy. EMBO J 2002;21:939-1947.
94. Semenza G. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002;64:993-8.
95. Vincent KA, Shyu KG, Luo Y, Magner M, Tio RA, Jiang C et al. Angiogenesis is induced in a rabbit model of hindlimb ischemia by naked DNA encoding an HIF-1alpha/VP16 hybrid transcription factor. Circulation 2000;102:2255-61.
96. Li J, Post M, Volk R, Gao Y, Li M, Metais C et al. PR39, a peptide regulator of angiogenesis. Nat Med 2000;6:49-55.
97. Gao Y, Lecker S, Post MJ, Hietaranta AJ, Li J, Volk R et al. Inhibition of ubiquitin-proteasome pathway-mediated I kappa B alpha degradation by a naturally occurring antibacterial peptide. J Clin Invest 2000;106:439-48.
98. Horowitz A, Simons M. Regulation of syndecan-4 phosphorylation in vivo. J Biol Chem 1998;273:10914-8.
99. Post MJ, Bao J, Sato K, Murakami M, Pearlman JD, Simons M. Adenoviral PR-39 improves perfusion and function in a pig model of chronic myocardial ischemia. Circulation 2002;106:1-275.
100. Simons M, Annex BH, Laham RJ, Kleiman N, Henry T, Dauerman H et al. Pharmacological treatment of coronary artery disease with recombinant fibroblast growth factor-2: double-blind, randomized, controlled clinical trial. Circulation 2002;105:788-93.
101. Henry TD, Annex BH, McKendall GR, Azrin MA, Lopez JJ, Giordano FJ et al. The VIVA trial: Vascular endothelial growth factor in Ischemia for Vascular Angiogenesis. Circulation 2003;107:1359-65.
102. Laham RJ, Sellke FW, Edelman ER, Pearlman JD, Ware JA, Brown DL et al. Local perivascular delivery of basic fibroblast growth factor in patients undergoing coronary bypass surgey: Results of a Phase I randomized, doublde-blind, placebo-controlled trial. Circulation 1999;100:1865-71.
103. Rual M, Laham RJ, Parker JA, Post MJ, Ware JA, Simons M et al. Long-term effects of angiogenic therapy with rFGF2 protein. J Thoracic Cardiovasc Surg 2002;124: 28-34.
104. Hedman M, Hartikainen J, Syvanne M, Stjernvall J, Hedman A, Kivela A et al. Safety and feasibility of catheter-based local intracoronary vascular endothelial growth factor gene transfer in the prevention of postangioplasty and in-stent restenosis and in the treatment of chronic myocardial ischemia: phase II results of the Kuopio Angiogenesis Trial (KAT). Circulation 2003;107:2677-83.
105. Losordo DW, Vale PR, Hendel RC, Milliken CE, Fortuin FD, Cummings N et al. Phase 1/2 placebo-controlled, double-blind, dose-escalating trial of myocardial vascular endothelial growth factor 2 gene transfer by catheter delivery in patients with chronic myocardial ischemia. Circulation 2002;105:2012-8.
106. Epstein SE, Kornowski R, Fuchs S, Dvorak HF. Angiogenesis therapy: amidst the hype, the neglected potential for serious side effects. Circulation 2001;104:115-9.
107. Folkman J. Role of angiogenesis in tumor growth and metastasis. Semin Oncol 2002;29:15-8.
108. Witmer AN, Vrensen GF, Van Noorden CJ, Schlingemann RO. Vascular endothelial growth factors and angiogenesis in eye disease. Prog Retin Eye Res 2003;22:1-29.
109. Celletti FL, Waugh JM, Amabile PG, Brendolan A, Hilfiker PR, Dake MD. Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nat Med 2001;7:425-9.
110. Moulton KS, Heller E, Konerding MA, Flynn E, Palinski W, Folkman J. Angiogenesis inhibitors endostatin or TNP-470 reduce intimal neovascularization and plaque growth in apolipoprotein E-deficient mice. Circulation 1999;99:1726-32.
111. Moulton KS, Vakili K, Zurakowski D, Soliman M, Butterfield C, Sylvin E et al. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc Natl Acad Sci U S A 2003;100:4736-41.
112. Post MI, Laham RJ, Kuntz RE, Novicki D, Simons M. The effect of intracoronary fibroblast growth factor-2 on restenosis after primary angioplasty or stent placement in a pig model of atherosclerosis. Clin Cardiol 2002;25:271-8.